Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02462629 · ClinicalTrials.gov registry record · Phase 1
Study of BLZ-100 in Pediatric Subjects With CNS Tumors
A Phase 1 study of Central Nervous System Tumors, sponsored by Blaze Bioscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02462629: Completed Phase 1 study of Central Nervous System Tumors, sponsored by Blaze Bioscience.
NCT02462629 is a Phase 1 study of Central Nervous System Tumors that has completed, run by Blaze Bioscience. The registered enrollment target is 29 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02462629, a Phase 1 study of Central Nervous System Tumors, has completed, sponsored by Blaze Bioscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor site, resulting in incomplete removal of the tumor and reduced patient survival. In some sites, such as the brain, it is critical to avoid damage to normal tissue around the tumor to prevent adverse effects of surgery on function. The investigators hypothesize that BLZ-100 will improve surgical outcomes by allowing surgeons to visualize the edges of the tumor and small groups of cancer cells that have spread to other sites in real-time as they operate. This is a safety study to assess the safety of BLZ-100 in pediatric patients with central nervous system tumors.
Primary Outcome
Safety will be assessed by physical examination and measurement of vital signs and laboratory safety parameters.
Conditions Studied
Interventions
- DRUG BLZ-100
Study Locations (1)
Washington
- Seattle Children's - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2015-06 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
What the finished NCT02462629 record still lists
NCT02462629 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (52% lower).
The record links to 1 condition, with Central Nervous System Tumors appearing as the primary indexed condition, and to 1 intervention - of which BLZ-100 is the first listed.
NCT02462629 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT02462629 about?
NCT02462629 is a clinical study titled "Study of BLZ-100 in Pediatric Subjects With CNS Tumors". Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed. It is often difficult for surgeons to distinguish tumor tissue from normal tissue or to detect tumor cells that have spread from the original tumor...
What is the current status of trial NCT02462629?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2015-06. Estimated completion is 2018-08.
What conditions does trial NCT02462629 study?
This clinical trial studies the following conditions: Central Nervous System Tumors.
What interventions are being tested in trial NCT02462629?
The interventions under investigation include: BLZ-100 (DRUG).
Who is sponsoring clinical trial NCT02462629?
This trial is sponsored by Blaze Bioscience, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02462629 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Central Nervous System Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02462629's enrollment target sits among peer trials
29 1440th of 2000 higher than 554 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia